Compare · CING vs NVO
CING vs NVO
Side-by-side comparison of Cingulate Inc. (CING) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CING and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.64B, about 3530.5x CING ($54.3M).
- Over the past year, CING is up 21.9% and NVO is down 40.8% - CING leads by 62.6 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 9 for CING).
- NVO has more recent analyst coverage (25 ratings vs 4 for CING).
- Company
- Cingulate Inc.
- Novo Nordisk A/S
- Price
- $4.90+20.25%
- $42.01-2.10%
- Market cap
- $54.3M
- $191.64B
- 1M return
- -5.41%
- -5.38%
- 1Y return
- +21.89%
- -40.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 9
- 11
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CING
- Cingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Cingulate Receives Complete Response Letter from FDA for CTx-1301
- SEC Form DEF 14A filed by Cingulate Inc.
- SEC Form DEFA14A filed by Cingulate Inc.
- Cingulate Inc. filed SEC Form 8-K: Leadership Update
- SEC Form PRE 14A filed by Cingulate Inc.
- SEC Form 10-Q filed by Cingulate Inc.
- Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- SEC Form 4 filed by EVP and CSO Silva Raul R.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates